期刊文献+

雷帕霉素对睾丸卵黄囊瘤细胞生长及凋亡的影响 被引量:1

Effect of rapamycin on growth and apoptosis of testicular yolk sac tumor cells
下载PDF
导出
摘要 目的研究雷帕霉素对睾丸卵黄囊瘤细胞的生长抑制和诱导凋亡作用。方法用不同浓度的雷帕霉素(1、10、50、100nmol/L)处理睾丸卵黄囊瘤细胞,设空白组和阴性对照组。采用CCK-8法测定不同浓度雷帕霉素对细胞生长的影响;采用流式细胞仪检测不同浓度雷帕霉素对细胞周期及凋亡的影响。结果雷帕霉素可以抑制睾丸卵黄囊瘤细胞生长,呈浓度依赖性和时间依赖性,除1nmol/L浓度组外,其余浓度组各时间点的细胞生长抑制率与阴性对照组比较差异均有统计学意义(均P<0.05)。雷帕霉素可以诱导睾丸卵黄囊瘤细胞凋亡,使细胞停留在G0/G1期,除1nmol/L浓度组外,其余浓度组G0/G1期细胞比例及细胞凋亡率显著高于阴性对照组,差异均有统计学意义(均P<0.05)。结论雷帕霉素能够抑制睾丸卵黄囊瘤细胞的生长,促进细胞凋亡。 Objective To investigate the effect of rapamycin on the growth and apoptosis in testicular yolk sac tumor(YST) cells.Methods The testicular YST cells were treated with rapamycin of different concentrations(1 nmol/L, 10 nmol/L, 50 nmol/L and 100 nmol/L).The growth rate for testicular YST cells was evaluated by CCK-8 method, the cell cycle and apoptosis rate were determined by flow cytometry.Results Rapamycin inhibited the growth of testicular YST cells in a concentration and time-dependent manner(P 0.05). Rapamycin at all concentrations except 1 nmol/L induced the apoptosis of testicular YST cells, and also induced cell cycle arrest at G0/G1 phase(P 0.05).Conclusion Rapamycin can significantly inhibit the cell growth and induce the apoptosis of testicular YST cells.
出处 《浙江医学》 CAS 2017年第22期2016-2018,2026,共4页 Zhejiang Medical Journal
基金 温州市科技局资助项目(Y20140243) 国家卫生计生委资助项目(2011C1-80)
关键词 卵黄囊瘤 雷帕霉素 细胞生长 细胞凋亡 Yolk sac tumor Rapamycin Cell growth Cell apoptosis
  • 相关文献

参考文献1

二级参考文献15

  • 1Oosterhuis JW, Looijeoga LH. Testicular germ-cell tttmours in a broader perspective Nat Rev Cancer,2005,5(3) :210-222.
  • 2Walsh TJ, Grady RW, Porter MP, et al. Incidence of testicu- lar germ cell cancers in US. children: SEER program experience 1973 to 2000. Urology.2006.68(2),402-405.
  • 3Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activi- ty of SU11248, a novel tyrosine kinase inhibitor targeting vas- cular endothelial growth factor and platelet-derived growth fac- tor receptors: determination of a pharmacokinetic/pharmaco- dynamic relationship. Clin Cancer Res, 2003,9 (1) : 327-337.
  • 4Abrams TJ, Lee LB, Murray LJ, et al. SUl1248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther, 2003,2 (5) : 471-478.
  • 5O'Farrell AM, Abrams TJ, Yuen HA, et al. SUl1248 is a no- vel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood,2003,101(9) :3597-3605.
  • 6Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activi- ty of SU11248, a novel tyrosine kinase inhibitor targeting vas- cular endothelial growth factor and platelet-derived growth fac- tor receptors: determination of a pharmacokinetic/pharmaco- dynamic relationship. Chn Cancer Res,2003,9(1):327-337.
  • 7Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol, 2009,16(2) : 125-129.
  • 8Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in earlystage breast carcinoma. J Natl Cancer Inst, 1992, 84 (24): 1875-1887.
  • 9Devouassoux-Shisheboran M, Mauduit C, Tabone E, et al. Growth regulatory factors and signalling proteins in testicular germ cell tumours: APMIS, 2003,111 (1) : 212-224.
  • 10O'Farrell AM, Abrams TJ, Yuen HA, et al. SUl1248 is a no- vel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, 2003,101 (9) : 3597-3605.

共引文献1

同被引文献14

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部